Trial Profile
Phase II trial of Ifenprodil for COVID-19 infection
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 28 Nov 2020
At a glance
- Drugs Ifenprodil (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
- Sponsors Algernon Pharmaceuticals
- 13 Nov 2020 According to an Algernon Pharmaceuticals media release, the company will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held on November 13, 2020
- 06 Apr 2020 New trial record
- 02 Apr 2020 According to an Algernon Pharmaceuticals media release, the company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly.
Most Recent Events
Trial Overview
Purpose
This trial will evaluate Ifenprodil for COVID-19 infection.
Diseases Treated
| Indication | Qualifiers | Patient Segments |
|---|---|---|
| COVID 2019 infections | treatment | - |
Subjects
- Subject Type patients
- Sex male & female
Trial Details
Organisations
- Sponsors Algernon Pharmaceuticals
- Affiliations Algernon Pharmaceuticals
Trial Dates
Other Details
- Design prospective
- Phase of Trial Phase II
- Location Australia
- Focus Therapeutic Use
Interventions
| Drugs | Route | Formulation |
|---|---|---|
| IfenprodilPrimary Drug | Oral |
-
|
Ifenprodil
Trial Centres
Trial History
| Event Date | Event Type | Comment |
|---|---|---|
| 13 Nov 2020 | Other trial event | According to an Algernon Pharmaceuticals media release, the company will be providing an update on its Ifenprodil Phase 2 human clinical studies presented by Christopher J. Moreau, CEO and Dr. Mark Williams, CSO and hosted by Dr. KSS MD PhD. The BioPub webcast will be held on November 13, 2020 Updated 28 Nov 2020 |
| 06 Apr 2020 | New trial record | New trial record Updated 06 Apr 2020 |
| 02 Apr 2020 | Other trial event | According to an Algernon Pharmaceuticals media release, the company is working to prepare all documentation for an ethics approval submission in Australia, which will be filed shortly. Updated 14 Apr 2020 |
| 02 Apr 2020 | Other trial event | According to an Algernon Pharmaceuticals media release, the decision to conduct this study is based on the results of a recently conducted successful feasibility study. Updated 06 Apr 2020 |
| 02 Apr 2020 | Other trial event | According to an Algernon Pharmaceuticals media release, the company has retained Novotech to conduct this study. Updated 06 Apr 2020 |
References
-
Algernon Pharmaceuticals. Algernon Provides Update on Phase 2 Human Testing of Ifenprodil for COVID-19. Media-Rel 2020;.
Media Release -
Algernon Pharmaceuticals. Algernon Pharmaceuticals Provides Update on its Ifenprodil Phase 2 Clinical Trials Featured on BioPub Webcast Hosted by Dr. KSS MD PhD. Media-Rel 2020;.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG